Abstract
LDL-lowering therapies, predominantly involving statins, have been shown to significantly reduce cardiovascular events in asymptomatic subjects as well as in subjects with clinically established atherosclerotic cardiovascular disease. However, despite statin therapy, significant number of cardiovascular events continue to occur indicating the need for additional targets for atherosclerosis management. A number of pre-clinical studies have suggested that several HDL based therapies have the potential to stabilize or regress atherosclerosis consistent with epidemiologic evidence of an inverse relationship between coronary heart disease and HDL cholesterol levels. One such therapeutic approach involves direct infusion of HDL or HDL like molecules for rapid remodeling and stabilization of atherosclerosis. Pre-clinical and proof of concept type preliminary clinical studies suggest the feasibility and potential efficacy of this emerging new therapeutic paradigm.
Keywords: Atherosclerosis, HDL, Reverse cholesterol transport
Current Pharmaceutical Design
Title: Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach
Volume: 13 Issue: 10
Author(s): P. K. Shah
Affiliation:
Keywords: Atherosclerosis, HDL, Reverse cholesterol transport
Abstract: LDL-lowering therapies, predominantly involving statins, have been shown to significantly reduce cardiovascular events in asymptomatic subjects as well as in subjects with clinically established atherosclerotic cardiovascular disease. However, despite statin therapy, significant number of cardiovascular events continue to occur indicating the need for additional targets for atherosclerosis management. A number of pre-clinical studies have suggested that several HDL based therapies have the potential to stabilize or regress atherosclerosis consistent with epidemiologic evidence of an inverse relationship between coronary heart disease and HDL cholesterol levels. One such therapeutic approach involves direct infusion of HDL or HDL like molecules for rapid remodeling and stabilization of atherosclerosis. Pre-clinical and proof of concept type preliminary clinical studies suggest the feasibility and potential efficacy of this emerging new therapeutic paradigm.
Export Options
About this article
Cite this article as:
Shah K. P., Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach, Current Pharmaceutical Design 2007; 13 (10) . https://dx.doi.org/10.2174/138161207780487520
DOI https://dx.doi.org/10.2174/138161207780487520 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran
Cardiovascular & Hematological Disorders-Drug Targets Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Editorial from Guest Editor [Hot Topic Perinatal Stem Cells Revisited: Directions and Indications at the Crossroads Between Tissue Regeneration and Repair]
Current Stem Cell Research & Therapy Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic Acid as Novel Fibrinogen Receptor Antagonists
Medicinal Chemistry Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama
Current Aging Science Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design New Strategies and Paradigm for Drug Target Discovery: A Special Focus on Infectious Diseases Tuberculosis, Malaria, Leishmaniasis, Trypanosomiasis and Gastritis
Infectious Disorders - Drug Targets Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design